Investigators Workshop |Anatomical and Neurobehavioral Consequence of Fetal Antiseizure Medication Exposure

Saturday, December 4, 2021
-

You may need to log in to view video on this page.

OVERVIEW:

This workshop invites a timely and multi-disciplinary dialog on the topic of anatomical, structural, and neurodevelopmental consequences of fetal antiseizure medication (ASM) exposure.  

Presenters review the latest clinical data available from registry studies and critically evaluate the translational potential of preclinical models.  

The discussion aims to identify transformative translational research priorities for the future, not limited to: 

  1. Developing a deeper understanding of the genetic and/or epigenetic mechanisms of ASM-induced teratogenesis 
  2. Defining avenues to design new, safe and effective ASM for use in pregnancy 

Learning Objectives:

Following participation in this activity, participants will be able to: 

  • Develop a scientifically informed framework to assess how the pharmacodynamic and pharmacokinetic properties ASM may raise the risk of teratogenesis 
  • Evaluate the translational potential of classical and novel, more innovative preclinical platforms actively employed to screen for ASM teratogenicity 
  • Appraise the possible future role of maternal genetic biomarkers in refining seizure preventative strategies in pregnant patients

Program:

Moderators: Vaishnav Krishnan, MD, PhD and Kimford J. Meador, MD, FAES 

Speakers: Robert Cabrera, PhD; Yi Li, MD, PhD and Vaishnav Krishnan, MD, PhD

Activity Type
Investigators Workshop
Credit
Non-CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Behavioral Health Providers
Clinicians
Fellows/Trainees
Pharmacists
Scientists/Researchers
Technicians
Demographic
Clinical
Research
Young Professionals